10-K: Carlsmed Reports Strong Growth, Expands Spine Surgery Platform

Carlsmed, Inc. achieved significant revenue growth and expanded its AI-enabled personalized spine surgery platform into cervical fusion, backed by strong clinical evidence and favorable reimbursement updates.

Summary

• Carlsmed, Inc. is a commercial-stage medical technology company specializing in AI-enabled personalized spine surgery solutions, aiming to become the standard of care for spine fusion.
• The aprevo Technology Platform provides personalized digital surgical plans and custom-designed interbody implants for lumbar and cervical spine fusion surgeries.
• Revenue for the year ended December 31, 2025, was $50.5 million, an 85.9% increase from $27.2 million in 2024.
• Gross margin improved to 75.3% in 2025 from 73.8% in 2024, driven by enhanced manufacturing efficiencies.
• Net loss increased to $29.6 million in 2025 from $24.3 million in 2024, primarily due to increased operating expenses for growth initiatives.
• The company completed its Initial Public Offering (IPO) on July 24, 2025, raising $93.5 million in net proceeds.
• FDA 510(k) clearance for aprevo cervical interbody implants was received in November 2024, with commercialization commencing in December 2025.
• FDA 510(k) clearance for the cervical plating system was received in December 2025, with the first personalized plating procedure completed in February 2026.
• CMS finalized X-codes and a New Technology Add-on Payment (NTAP) of up to $21,125 for qualifying inpatient cervical spine fusion procedures using aprevo, effective October 1, 2025.
• The aprevo Technology Platform has been used to treat over 3,200 patients by 253 surgeon users as of December 31, 2025, up from 152 in 2024.
• Clinical studies demonstrate improved post-operative alignment and significantly reduced revision rates (e.g., 4.3% for aprevo vs. 16.6% for stock implants in ASD patients at two years, a 74% relative reduction).
• The company maintains a robust intellectual property portfolio with 45 issued patents and approximately 120 pending applications, alongside a significant data moat of over four million de-identified radiographic images.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, reflecting robust revenue growth, significant product expansion into new indications with favorable regulatory and reimbursement outcomes, and compelling clinical evidence. While net losses increased due to strategic investments, the underlying business momentum and market penetration are highly encouraging for future profitability.

Positives

• Achieved substantial revenue growth of 85.9% year-over-year, reaching $50.5 million in 2025.
• Improved gross margin to 75.3% in 2025, indicating enhanced manufacturing efficiencies and process improvements.
• Successfully expanded the aprevo Technology Platform into cervical spine fusion with FDA 510(k) clearances in November 2024 and December 2025, and commenced commercialization in December 2025.
• Secured favorable reimbursement with CMS finalizing X-codes and a New Technology Add-on Payment (NTAP) of up to $21,125 for inpatient cervical spine fusion procedures, effective October 1, 2025.
• Strong clinical evidence supports the platform's benefits, including a 74% relative reduction in mechanical complication-related reoperations for ASD patients compared to stock implants (4.3% vs. 16.6% at two years).
• Demonstrated zero revision surgeries for adjacent segment degeneration in DDD patients at 20-month median follow-up in a COMPASS study.
• Expanded surgeon user base to 253 by December 31, 2025, from 152 in 2024, indicating growing market adoption.
• Maintains a robust intellectual property portfolio with 45 issued patents and approximately 120 pending applications, covering implants, manufacturing, design, software, and AI algorithms.
• Operates a scalable, inventory-light business model with patient-specific implants manufactured on-demand, allowing for delivery within six business days of surgical plan approval as of February 2026.
• Completed a successful IPO in July 2025, raising $93.5 million in net proceeds to fund commercialization and R&D.

Negatives

• Incurred increased net losses, rising to $29.6 million in 2025 from $24.3 million in 2024, and an accumulated deficit of $100.8 million as of December 31, 2025.
• Operating expenses increased significantly, with sales and marketing up 63.1% and general and administrative up 97.4% in 2025.
• Reliance on a limited number of Contract Manufacturing Organizations (CMOs) for all manufacturing, which could pose risks to supply and cost control.
• The requested Transitional Pass-Through (TPT) payment for aprevo cervical in outpatient settings was not approved by CMS in November 2025, potentially impacting outpatient reimbursement.
• The company has a limited operating history, making it difficult to evaluate future prospects and manage business fluctuations effectively.
• Subject to intense competition from larger, well-capitalized medical device companies with greater market share and resources.

Risks

• Dependence entirely on sales of aprevo interbody implants for revenue; failure to achieve substantial market acceptance and adoption would harm the business.
• Limited operating history and periods of significant business changes make it difficult to evaluate future prospects and manage business effectively.
• History of net losses and expectation to incur additional substantial losses in the foreseeable future.
• Business and growth strategy depend on the ability to broadly commercialize the aprevo Technology Platform for cervical spine fusion surgeries; failure to do so would limit future growth.
• Managing the on-demand, customized implant model to address evolving demand is expensive, time-consuming, and subject to uncertainties, potentially leading to delays and loss of customers to competitors.
• Reliance on a limited number of CMOs for manufacturing, treatment, sterilization, packaging, and distribution increases the risk of insufficient quantities, unacceptable costs, and reduced control over the manufacturing process.
• If third parties assisting with premarket development activities for future products do not perform as required, regulatory clearance or approval may not be obtained, or commercialization may be unsuccessful.
• Operating in a highly competitive industry where new developments by competitors could render the aprevo Technology Platform non-competitive or obsolete.
• Future sales in international markets will subject the company to additional costs and risks, including regulatory hurdles and different reimbursement pathways.
• Inability to successfully develop new products, effectively manage their introduction, or improve existing products could adversely affect the business.
• Exposure to product and other liability claims, including those related to serious complications from spine surgeries or off-label use of implants, which could require substantial payments.
• A recall of products, voluntary or mandated, or discovery of serious safety issues, could have a significant adverse impact on the company.
• The estimated total addressable market may be smaller than projected, impacting growth prospects.
• Discovery of alternative technologies or other personalized spinal implant technologies could materially adversely affect the business.
• Quarterly and annual results may fluctuate significantly due to various factors, potentially decreasing common stock value.
• Macroeconomic conditions (inflation, interest rates, geopolitical conflicts) could materially adversely affect the business, including demand for elective spine surgeries.
• Cybersecurity risks could materially affect business, operations, or financial condition, leading to data loss, operational interruptions, or reputational damage.
• Continued commercialization depends on third-party payor coverage and adequate reimbursement levels; failure to maintain these could limit marketing and revenue generation.
• Actual or perceived failures to comply with data privacy and security laws (e.g., HIPAA, CCPA, GDPR) could lead to regulatory inquiries, fines, litigation, and reputational harm.
• Failure to comply with healthcare and other governmental regulations (e.g., Anti-Kickback Statute, False Claims Act) could result in substantial penalties or exclusion from government programs.
• Success depends on the ability to obtain, maintain, enforce, and protect intellectual property rights; challenges to patents or trade secrets could harm competitive position.
• Use and development of AI Technologies presents regulatory, operational, intellectual property, performance, and reputational risks, with evolving AI-related laws increasing compliance burdens.
• Indebtedness under the Customers Loan Agreement subjects the company to financial and operational covenants that restrict flexibility and could trigger default.
• Cash deposits with financial institutions exceed insured limits, posing a risk in case of bank failures.

Future Outlook

Carlsmed intends to broadly commercialize its aprevo cervical platform, including the corra Cervical Plating System, in 2026 and expects to drive adoption with existing lumbar surgeons. The company plans to continue investing in R&D to enhance the aprevo Technology Platform, introduce new capabilities, and explore additional indications within the spine (e.g., cervical corpectomy, cervical disc arthroplasty) and potentially other musculoskeletal applications. The commercial launch of the aprevo Lumbar Bi-lateral Posterior System (PLIF) is expected in the first half of 2026. The company anticipates continued sequential quarterly and annual revenue growth, with gross margin modestly increasing over the medium and long term due to economies of scale and AI leverage.

Management Comments

• We believe that the unique and differentiated benefits of the aprevo Technology Platform have helped drive strong adoption since our commercial launch.
• We are committed to building upon our strong foundation of clinical evidence demonstrating the efficacy of the aprevo Technology Platform.
• We believe that investment in research and development is critical to achieving our goal of establishing the aprevo Technology Platform as the standard of care for spine fusion and expanding its use into additional disease states.
• We expect to continue to increase our sales territories and our independent sales agents in the United States to deepen our penetration in existing markets and expand into new geographic territories.
• We believe that the overall escalating cost of medical products and services being paid for by the government and private health insurance has led to, and will continue to lead to, increased pressures on the healthcare and medical device industries to reduce the costs of products and services.

Industry Context

StockSavvy.ai notes that Carlsmed operates in the highly competitive medical device industry, specifically targeting the spine fusion market, which is characterized by rapid technological change. The company's AI-enabled personalized approach positions it as a disruptor against traditional stock implant manufacturers like Medtronic PLC, Johnson & Johnson, and Globus Medical Inc. The significant unmet clinical need in degenerative disc disease (DDD) and adult spinal deformity (ASD), coupled with the economic burden of revision surgeries, provides a substantial market opportunity for Carlsmed's differentiated technology. Favorable reimbursement changes from CMS for both lumbar and cervical procedures are critical tailwinds, aligning with broader industry trends towards value-based care and personalized medicine. The company's focus on building a robust clinical evidence base is essential for gaining market acceptance and competitive advantage in a field where clinical outcomes are paramount.

Comparison to Industry Standards

• aprevo's 4.3% reoperation rate at two years for ASD patients (n=115) compares favorably to 16.6% for patients treated with stock implants (n=997) in a December 2025 Global Spine Journal publication, representing a 74% relative reduction. This is also significantly better than the average two-year revision rate of 24.9% noted in three other published studies for mechanical complications.
• Interim data from the COMPASS Registry showed a 1.5% revision rate at one-year follow-up for ASD patients treated with aprevo, compared to reported rates of 14% to 32% over one to two years for traditional spine fusions in ASD patients.
• A study on 90 COMPASS patients with DDD using aprevo demonstrated zero revision surgeries for adjacent segment degeneration at 20-month median follow-up, contrasting with other studies showing a 25.9% revision rate for patients with unrestored distal lumbar lordosis (DLL) at minimum two-years follow-up.
• In a multicenter study of 65 ASD patients, 44.6% achieved targeted PI-LL within five degrees using aprevo, significantly outperforming the 31.5% achieved by an International Spine Study Group (ISSG) cohort of 266 ASD patients using stock implants (P = 0.046).
• aprevo also led to a significant reduction in cases where the PI-LL target was missed by greater than 15 degrees (15.3% vs. 30.8%, P = 0.012) compared to ISSG cases.
• In a study of 135 DDD patients, 44% of pre-operatively malaligned patients achieved PI-LL restoration to less than 10 degrees with aprevo, a statistically significant improvement over the 29% restoration rate observed in a multicenter study of 578 patients using stock implants.

Corporate Governance

Legal Proceedings

• The company is from time to time involved in legal matters incidental to the conduct of its business. Management believes there are no claims outstanding that would have a material adverse effect on the company's financial position, results of operations, or cash flows.

Related Party Transactions

• The company has entered into advisory board and consulting agreements with physicians, including some who have ownership interests and/or influence the ordering or use of products. Compensation under some of these arrangements includes stock or stock options.

Stakeholder Impact

• **Shareholders:** Potential for long-term value appreciation due to strong revenue growth, market expansion, and positive clinical outcomes, but also exposure to continued net losses and competitive risks. Anti-takeover provisions may limit opportunities for premium acquisition offers.
• **Employees:** Continued growth and investment in R&D and commercial infrastructure suggest job stability and potential for career advancement. Stock-based compensation plans provide incentives.
• **Customers (Hospitals & ASCs):** Benefit from premium reimbursement for using aprevo products, potentially improving their financial outcomes. Access to innovative, personalized spine surgery solutions can enhance patient care and reduce revision surgeries.
• **Surgeons:** Provided with advanced AI-enabled tools and personalized implants that aim to improve surgical outcomes and reduce complications. Training programs support adoption. However, reliance on timely delivery from CMOs is a factor.
• **Patients:** Benefit from personalized surgical plans and implants designed to optimize outcomes, improve spinal alignment, and significantly reduce the need for revision surgeries, leading to improved health and quality of life.
• **Creditors (Customers Bank):** The company is in compliance with loan covenants, and the expanded credit facility provides additional liquidity, reducing immediate credit risk.

Next Steps

• Broadly commercialize the aprevo Technology Platform for cervical spine fusion surgeries, including the anticipated commercial launch of the corra Cervical Plating System in 2026.
• Commercial launch of the aprevo Lumbar Bi-lateral Posterior System (PLIF) is expected in the first half of 2026.
• Continue to drive adoption and market share capture for aprevo in lumbar fusion surgeries by growing commercial infrastructure, expanding market access initiatives, and utilizing medical education programs.
• Invest in further growing the base of clinical evidence, including generating real-world evidence from the COMPASS Registry and conducting studies for cervical spine fusion.
• Continue to develop research and development initiatives to introduce enhancements, new capabilities, and address additional indications and disease states within the spine (e.g., cervical corpectomy, cervical disc arthroplasty) and potentially other musculoskeletal applications.
• Complete data from the 338-patient COMPASS Registry is anticipated to be released in the first half of 2027.

Key Dates

Recommendation

Carlsmed demonstrates exceptional revenue growth (85.9% YoY) and improving gross margins, driven by a highly innovative AI-enabled personalized spine surgery platform. Recent FDA clearances for cervical fusion and favorable reimbursement updates from CMS significantly expand its addressable market and enhance its competitive position. Strong clinical data consistently shows superior patient outcomes, including substantially reduced revision rates compared to traditional methods. While the company is still incurring net losses due to aggressive investment in R&D and commercial expansion, these are strategic expenditures aimed at capturing a large and underserved market. The successful IPO provides substantial capital for continued growth. The combination of strong technological differentiation, validated clinical efficacy, expanding market access, and robust financial backing makes Carlsmed a compelling 'buy' for investors seeking exposure to high-growth medical technology with significant long-term potential, despite the inherent risks of a growth-stage company.

Keywords

AI-enabled spine surgery, Personalized implants, Spine fusion, Medical technology, Degenerative disc disease, Adult spinal deformity, FDA clearance, Reimbursement, Surgical planning software, Interbody implants, Orthopedic devices, Biomedical engineering, Healthcare innovation, Digital health, Surgical instruments, Intellectual property, Clinical outcomes, Revision surgery reduction, Nasdaq